Insider Selling: Roivant Sciences (NASDAQ:ROIV) CAO Sells 13,538 Shares of Stock

Key Points

• Insider sale: CAO Jennifer Humes sold 13,538 shares on April 8 at an average price of $28.37 for proceeds of $384,073, reducing her stake by 13.85% to 84,191 shares (valued at about $2.39M).
• Institutional inflows: Major firms including UBS, Morgan Stanley, Goldman Sachs and Assenagon significantly increased positions in the fourth quarter and Norges Bank opened a new position, leaving roughly 64.76% of the stock owned by hedge funds and other institutions.
• Analyst outlook: Nine analysts rate ROIV a Buy (one Hold, one Sell) with an average price target of $29.50, while the stock trades near $28.21 and has a 12‑month high of $30.33.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total transaction of $384,073.06. Following the completion of the transaction, the chief accounting officer directly owned 84,191 shares of the company's stock, valued at $2,388,498.67. The trade was a 13.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Roivant Sciences Trading Down 0.9%

Shares of Roivant Sciences stock traded down $0.27 during trading hours on Friday, reaching $28.21. The stock had a trading volume of 3,119,893 shares, compared to its average volume of 6,200,035. The stock's 50 day moving average is $27.26 and its 200 day moving average is $22.54. Roivant Sciences Ltd. has a twelve month low of $9.57 and a twelve month high of $30.33. The firm has a market capitalization of $20.19 billion, a PE ratio of -24.11 and a beta of 1.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS Group AG grew its stake in Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company's stock worth $399,080,000 after purchasing an additional 15,645,836 shares in the last quarter. Morgan Stanley boosted its stake in shares of Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company's stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company's stock valued at $238,323,000 after buying an additional 8,621,567 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Roivant Sciences by 11,507.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company's stock worth $150,535,000 after buying an additional 6,877,348 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Roivant Sciences during the fourth quarter worth about $112,750,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ROIV shares. TD Cowen restated a "buy" rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Leerink Partners raised their target price on Roivant Sciences from $29.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, December 15th. Citigroup boosted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a research note on Tuesday, February 10th. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They set an "outperform" rating and a $35.00 price objective for the company. Finally, Guggenheim lifted their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a "buy" rating in a report on Monday, February 9th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.50.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.